{"analyses":[{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.91","estimateComment":"Hazard ratios (HRs) were estimated using a Pike estimator.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.73"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"12.8","value":"10.2"},{"groupId":"OG001","lowerLimit":"5.9","upperLimit":"9.3","value":"8.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"212"}],"units":"Participants"}],"description":"PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started. In addition, the sum must have an absolute increase from nadir of 5 mm. The appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation, was also included as PD. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not have documented progression or death, PFS was censored at the date of the last adequate assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dabrafenib 150 milligram (mg) HPMC capsules orally twice daily (BID), once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib 2 mg once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib + Trametinib"},{"description":"Participants received dabrafenib 150 mg HPMC capsules orally BID, once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib placebo once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent. Crossover to the combination therapy arm was allowed for subjects still receiving study treatment on the dabrafenib monotherapy arm after the positive result for the final OS analysis.","id":"OG001","title":"Dabrafenib + Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population was considered.","reportingStatus":"POSTED","timeFrame":"From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)","title":"Progression-Free Survival (PFS) as Assessed by the Investigator","type":"PRIMARY","unitOfMeasure":"Months"}